Affimed Presents Findings from the Dose-escalation Phase of the First-in-human Study of AFM24 in Patients with EGFR-positive Solid Tumors
The recommended phase 2 dose was determined at 480 mg AFM24 has demonstrated a well-managed…
News
Aadi Bioscience Announces Data Presentation on incidence of TSC1 and TSC2 Alterations in Advanced Cancers at the Annual Meeting of the American Association for Cancer Research (AACR)
– First rigorous analysis estimates TSC1 and TSC2 definite impact alteration incidence in U.S. as…
Adagene Presents Data Demonstrating First and Best-in-Class Potential for Differentiated Preclinical Antibody Candidates at American Association for Cancer Research (AACR) Annual Meeting 2022
– Poster presentations showcase SAFEbody® precision masking technology applicability across targets and modalities – –…
Kronos Bio Presents Preclinical Data on Oral CDK9 Inhibitor KB-0742, Providing Additional Evidence of Potential Efficacy in MYC-Amplified and Transcriptionally Addicted Tumors at AACR
Preclinical data featured in three posters show potential of KB-0742 in triple-negative breast, lung and…
Pyxis Oncology Announces Preclinical Data on Anti-Siglec-15 BSI-060T (PYX-106) Presented by Biosion, Inc. at the 2022 American Association for Cancer Research (AACR) Annual Meeting
– Data highlight PYX-106’s differentiated activity profile and antitumor activity in an in vivo mouse…
Vincerx Pharma Presents Preclinical and Preliminary Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Gynecologic Malignancies at the American Association for Cancer Research (AACR) Annual Meeting 2022
VIP152 demonstrates antitumor responses in preclinical models of gynecologic malignancies Preliminary monotherapy clinical results presented…
X4 Pharmaceuticals to Present at the 2022 American Association for Cancer Research (AACR) Annual Meeting 2022
BOSTON, April 08, 2022 (GLOBE NEWSWIRE) — X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in…
BlueSphere Bio Presents New Data Supporting the Potential of its TCXpressâ„¢ Platform at the 2022 AACR Meeting
TCXpress™ identified a diverse set of novel T-cell receptors (TCRs) with in vitro reactivity against…
Araris Biotech AG Presents Preclinical Data Highlighting Anti-CD79b ADC Program and Late-Breaking Data on Nectin-4 ADC at the American Association for Cancer Research (AACR) 2022 Annual Meeting
ZURICH, Switzerland, April 08, 2022 (GLOBE NEWSWIRE) — Araris Biotech AG, a company pioneering a…
Genocea Presents Encouraging Initial Data from GEN-011 Phase 1/2a Trial at AACR 2022
GEN-011 shows consistent pattern of activity in first five heavily pre-treated, checkpoint-refractory patients with…
Kymera Therapeutics Presents Preclinical Data Highlighting Biological Superiority of MDM2 Degradation over Inhibition and Shares Profile of Clinical Candidate KT-253 at the American Association for Cancer Research (AACR) Annual Meeting 2022
MDM2 degradation demonstrated differentiated biological activity and superior cell killing compared to small molecule inhibition…
Nurix Therapeutics Presents New Preclinical Data Supporting NX-2127 and DeTIL-0255 Clinical Programs at the American Association for Cancer Research Annual Meeting
Studies provide insight into bifunctional molecular mechanism and first in vivo demonstration of immunomodulatory imide…
Umoja Biopharma Presents Data on its iPSC-Based Cell Therapy Platform at the American Association for Cancer Research (AACR) Annual Meeting 2022
Data demonstrates the potential for de novo engineering of novel synthetic cytotoxic effector cells that show significant…
Calithera Presents Data Highlighting Discovery of Novel Series of Promising Synthetic Lethal Compounds
Findings presented today at AACR Annual Meeting detail Calithera discovery of VPS4A inhibitors and their…
Checkmate Pharmaceuticals Presents Clinical Trial Biomarker Data with Vidutolimod at the 2022 American Association for Cancer Research (AACR) Annual Meeting
CAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) — Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company…
Adaptimmune Presents MAGE-A4 Expression Data from its Screening Protocol at AACR Confirming Expression Across a Broad Range of Solid Tumors
– Data from multiple solid tumor indications confirms that MAGE-A4 is a broadly expressed cancer…
iOnctura Presents Data at AACR Demonstrating its Unique Mechanism of Action for Clinical Stage ATX Inhibitor IOA-289
GENEVA, Switzerland, April 08, 2022 (GLOBE NEWSWIRE) — iOnctura SA, a clinical-stage oncology company targeting…
Agenus Presents Data on AGEN1571 (anti-ILT2) at AACR and Announces IND Clearance
First data presentation on AGEN1571 shows strong adaptive and innate immune responses Preclinical data indicate…
Kura Oncology Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergence of Resistance to Osimertinib in Non-Small Cell Lung Cancer
– Late-breaking presentation at AACR demonstrates potential to significantly delay onset of drug resistance to…
iTeos Presents New Data for Anti-TIGIT Antibody, EOS-448/GSK4428859A, at the AACR Annual Meeting 2022
Treatment with EOS-448 results in a decrease of TIGIT-positive cells in tumor biopsies, the first…